EGFR-TKI靶向药物已成为肺癌一线治疗方法，但单纯依靠EGFR突变的筛选，难以准确评价和预测肺癌EGFR-TKI的治疗效果。KRAS是与EGFR调控功能高度重叠的“分子开关”，KRAS突变会显著降低甚至完全消除肺癌对EGFR-TKI的治疗响应，是指南公认的重要疗效预测标志。然而，目前尚无KRAS突变的可视化检测方法，以克服传统手段在异质性和灵敏度上的短板。本研究拟在课题组前期PET探针改构转化、肺癌影像组学研究的基础上，以新问世的KRAS突变抑制剂AMG510和ARS1620为基础，构建并筛选KRAS突变靶向PET探针，为KRAS突变可视化提供新的分子影像手段，阐明其显像效果及EGFR-TKI疗效预测效能；并且基于KRAS PET/CT影像，辅以基因检测、肿瘤标志物等信息，建立精准预测EGFR-TKI疗效的影像组学算法，为EGFR-TKI的疗效评价提供更精准的影像组学策略。

EGFR-TKI targeted therapy has become the first-line treatment for lung cancer, but the screening of patients solely by using EGFR mutation as a therapeutic efficacy predictor has prominent problems of unstable response rate and unclear survival benefit. KRAS is a "molecular switch" that highly overlaps with the regulatory function of EGFR. KRAS mutation can significantly reduce or even completely eliminate the therapeutic response of EGFR-TKI in lung cancer patients. As a result, KRAS mutation has been recognized as an important predictor of EGFR-TKI therapeutic efficacy. However, there is currently no visualized detection method for KRAS mutations to overcome the shortcomings of conventional methods in heterogeneity and sensitivity. Based on the previous experience of our lab on PET probe modification, clinical translation and lung cancer radiomics, this study is based on the newly developed KRAS mutation inhibitors AMG510 and ARS1620 to construct and screen KRAS mutant PET probes, and to investigate the imaging accuracy of this PET probe and its predictive efficacy of EGFR-TKI therapy. Further, based on KRAS PET/CT images, supplemented with clinical information of gene mutation sequencing and serum tumor markers, we plan to establish a radiomics algorithm that more accurately predicts the efficacy of EGFR-TKI therapy. This study can provide a radiomics strategy for accurately evaluating the therapeutic efficacy of EGFR-TKI in lung cancer.